A perspective analysis: companion diagnostics: an evolving paradigm in 21st century healthcare

FDA Perspective on Companion Diagnostics: An Evolving Paradigm

(2014) E. A. Mansfield   CLINICAL CANCER RESEARCH

Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union

(2014) F. Pignatti et al.   CLINICAL CANCER RESEARCH

EU data protection regulation—harming cancer research

(2014) David J. Kerr   Nature Reviews Clinical Oncology

Precision therapy for lymphoma—current state and future directions

(2014) Andrew M. Intlekofer et al.   Nature Reviews Clinical Oncology

Molecular analysis of circulating tumour cells—biology and biomarkers

(2014) Matthew G. Krebs et al.   Nature Reviews Clinical Oncology

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

(2014) Grzegorz J. Korpanty et al.   Frontiers in Oncology

Food and Drug Administration Approval of Laboratory Tests

(2013) Timothy Craig Allen   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Exosomes: the future of biomarkers in medicine

(2013) Francesca Properzi et al.   Biomarkers in Medicine

Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance

(2013) D Gonzalez de Castro et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A changing landscape for companion diagnostics

(2013) Jan Trøst Jørgensen   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Genomics-Driven Oncology: Framework for an Emerging Paradigm

(2013) Levi A. Garraway   JOURNAL OF CLINICAL ONCOLOGY

Designing Transformative Clinical Trials in the Cancer Genome Era

(2013) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

(2013) Tianhong Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour heterogeneity in the clinic

(2013) Philippe L. Bedard et al.   NATURE

First FDA Authorization for Next-Generation Sequencer

(2013) Francis S. Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Personalized medicine: is it a pharmacogenetic mirage?

(2012) Rashmi R. Shah et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Discovery of small molecule cancer drugs: Successes, challenges and opportunities

(2012) Swen Hoelder et al.   Molecular Oncology

Combinatorial drug therapy for cancer in the post-genomic era

(2012) Bissan Al-Lazikani et al.   NATURE BIOTECHNOLOGY

Overcoming regulatory and economic challenges facing pharmacogenomics

(2012) Joshua P. Cohen   New Biotechnology

Building bridges to the future of medicine: recommendations for boosting development of novel and companion diagnostics

(2012) James Creeden   PHARMACOGENOMICS

Clinical and economic challenges facing pharmacogenomics

(2012) J Cohen et al.   PHARMACOGENOMICS JOURNAL

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

(2012) T. Forshew et al.   Science Translational Medicine

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Drug–diagnostic co-development: how to harness the value

(2011) Edward D. Blair et al.   DRUG DISCOVERY TODAY

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

(2011) Vicki Leigh Keedy et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalized medicine in lung cancer: what we need to know

(2011) Tony S. K. Mok   Nature Reviews Clinical Oncology

Predictive biomarkers: a paradigm shift towards personalized cancer medicine

(2011) Nicholas B. La Thangue et al.   Nature Reviews Clinical Oncology

Market access challenges in the EU for high medical value diagnostic tests

(2011) Iain Miller et al.   Personalized Medicine

The BATTLE Trial: Personalizing Therapy for Lung Cancer

(2011) Edward S. Kim et al.   Cancer Discovery

Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR

(2010) Marie Brevet et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

(2010) Robert Pirker et al.   Journal of Thoracic Oncology

Proteomics of human cancer tissues and cells

(2010) Daniela Cecconi et al.   TRAC-TRENDS IN ANALYTICAL CHEMISTRY

Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer

(2009) J. Yu et al.   CLINICAL CANCER RESEARCH

I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

(2009) AD Barker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Epigenetics and cancer treatment

(2009) Lasse Sommer Kristensen et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies

(2009) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies

(2009) Chen Mao et al.   LUNG CANCER

The microeconomics of personalized medicine: today's challenge and tomorrow's promise

(2009) Jerel C. Davis et al.   NATURE REVIEWS DRUG DISCOVERY